Enterprise Value
-29.22M
Cash
113M
Avg Qtr Burn
N/A
Short % of Float
0.38%
Insider Ownership
32.69%
Institutional Own.
10.61%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ABI-4334 Details Liver disease, Liver infection, Hepatitis B | Phase 1b Data readout | |
ABI-5366 Details Genital herpes (HSV) | Phase 1a Data readout | |
Vebicorvir (VBR, ABI-H0731) Details Liver infection, Chronic liver disease, Hepatitis B | Failed Discontinued | |
ABI-H2158 Details Liver infection, Liver disease, Hepatitis B | Failed Discontinued | |
ABI-H3733 Details Liver disease, Hepatitis B, Liver infection | Failed Discontinued |